Regeneron Pharmaceuticals REGN Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's other income (expense)?
- Regeneron Pharmaceuticals (REGN) reported other income (expense) of $188.3M in Q1 2026.
- How has Regeneron Pharmaceuticals's other income (expense) changed year-over-year?
- Regeneron Pharmaceuticals's other income (expense) decreased by 39.9% year-over-year, from $313.3M to $188.3M.
- What is the long-term trend for Regeneron Pharmaceuticals's other income (expense)?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's other income (expense) has grown at a 139.8% compound annual growth rate (CAGR), from $119.9M to $1.65B.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.